InsiderTrades.com logo
Vladimir Lenin was right…
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.

PALI Insider Trading

Insider Ownership Percentage: 3.28%
Insider Buying (Last 12 Months): $15,664.00
Insider Selling (Last 12 Months): $0.00

Palisade Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Palisade Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palisade Bio Share Price & Price History

Current Price: $1.75
Price Change: ▼ Price Decrease of -0.05 (-2.78%)
As of 12/20/2024 06:31 PM ET

This chart shows the closing price history over time for PALI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Vladimir Lenin was right…
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.

Palisade Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/28/2024Donald Allen WilliamsDirectorBuy1,000$4.86$4,860.001,000View SEC Filing Icon  
5/24/2024John David FinleyCEOBuy1,000$4.81$4,810.008,437View SEC Filing Icon  
1/31/2024Donald Allen WilliamsDirectorBuy666$9.00$5,994.002,000View SEC Filing Icon  
9/27/2023Donald Allen WilliamsDirectorBuy1,333$8.10$10,797.301,333View SEC Filing Icon  
9/27/2023John David FinleyCEOBuy1,000$8.10$8,100.002,892View SEC Filing Icon  
9/14/2023Robert J. TrenschelDirectorSell20$9.60$192.00View SEC Filing Icon  
9/13/2023John David FinleyCEOBuy1,000$9.90$9,900.001,892View SEC Filing Icon  
8/23/2022John David FinleyCFOBuy490$2.40$1,176.008,616View SEC Filing Icon  
8/16/2022John David FinleyCFOBuy6,666$3.75$24,997.508,126View SEC Filing Icon  
8/16/2022Thomas HallamCEOBuy2,666$3.75$9,997.503,839View SEC Filing Icon  
3/29/2022Michael John DawsonInsiderBuy1,000$17.10$17,100.00View SEC Filing Icon  
3/28/2022Thomas HallamCEOBuy666$17.70$11,788.20View SEC Filing Icon  
3/24/2022John David FinleyCFOBuy500$16.35$8,175.00View SEC Filing Icon  
See Full Table
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW

SEC Filings (Institutional Ownership Changes) for Palisade Bio (NASDAQ:PALI)

11.79% of Palisade Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PALI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Palisade Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC27,858$0.13M0.0%-96.1%2.976%Search for SEC Filing on Google Icon
11/14/2022Altium Capital Management LP5,643,007$0.56M0.2%N/A25.791%Search for SEC Filing on Google Icon
10/27/2022Sargent Investment Group LLC670,000$76K0.0%+179.2%3.062%Search for SEC Filing on Google Icon
7/26/2022Sargent Investment Group LLC240,000$98K0.0%+84.6%1.097%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP333,954$0.43M0.1%N/A2.460%Search for SEC Filing on Google Icon
11/12/2021Sargent Investment Group LLC105,000$0.28M0.1%N/A0.812%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.28,841$76K0.0%+16.7%0.223%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC18,200$74K0.0%N/A0.160%Search for SEC Filing on Google Icon
8/16/2021State Street Corp28,210$0.12M0.0%N/A0.978%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC52,500$0.21M0.0%N/A1.821%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC145,300$0.59M0.0%N/A5.040%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP1,824,894$7.43M1.7%N/A63.298%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC24,675$100K0.0%N/A0.856%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.237,811$0.97M0.0%N/A8.249%Search for SEC Filing on Google Icon
8/12/2021Private Advisor Group LLC21,051$86K0.0%N/A0.730%Search for SEC Filing on Google Icon
8/6/2021HighTower Advisors LLC16,666$68K0.0%N/A0.578%Search for SEC Filing on Google Icon
7/31/2021Strategic Wealth Designers53,129$0.22M0.1%N/A1.845%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Read More on Palisade Bio

Today's Range

Now: $1.75
Low: $1.75
High: $1.86

50 Day Range

MA: $2.60
Low: $1.40
High: $3.91

52 Week Range

Now: $1.75
Low: $1.38
High: $22.35

Volume

120,416 shs

Average Volume

670,536 shs

Market Capitalization

$2.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Who are the company insiders with the largest holdings of Palisade Bio?

Palisade Bio's top insider investors include:
  1. John David Finley (CEO)
  2. Donald Allen Williams (Director)
  3. Robert J Trenschel (Director)
Learn More about top insider investors at Palisade Bio.
Vladimir Lenin was right…
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.